|
Loading...
| ||||||||||||||
Recent Publications by Allergy Therapeutics Ltd: |  | |
| A novel adjuvant complex, tyrosine-MPL, for prophylactic and therapeutic vaccines.
Therapeutic vaccination for the treatment of allergy has been used for... | Allergy Therapeutics Ltd., Dominion Way, Worthing, West Sussex, BN14 8SA, | Vaccine. 2006 Apr 12;24 Suppl 2:S2-40-1. |
| Modern approaches to therapeutic vaccination as treatment for type 1 respiratory hypersensitivity (allergy) treatment.
The incidence of respiratory and other allergies has increased... | Allergy Therapeutics Ltd, Worthing, West Sussex, BN14 8SA, UK. | Expert Rev Vaccines. 2006 Feb;5(1):27-31.
DOI Direct Link |
| Allergy vaccines--new approaches to an old concept.
Allergy vaccination (AV) consists of injecting increasing amounts of... | Allergy Therapeutics Ltd, Dominion Way, West Sussex, BN14 8SA, UK. | Expert Opin Biol Ther. 2004 Sep;4(9):1473-81.
DOI Direct Link |
| Standardisation of glutaraldehyde-modified tyrosine-adsorbed tree pollen vaccines containing the Th1-inducing adjuvant, monophosphoryl lipid A (MPL).
BACKGROUND: a new range of allergy vaccines has been developed by the... | Allergy Therapeutics Ltd, West Sussex, UK. | Allergol Immunopathol (Madr). 2001 Nov-Dec;29(6):245-54. |
| A Th1-inducing adjuvant, MPL, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines.
BACKGROUND: Monophosphoryl lipid A (MPL) is a detoxified derivative of the... | Allergy Therapeutics Ltd, Worthing, UK. | Int Arch Allergy Immunol. 2001 Oct;126(2):135-9. |